Study Highlights
- A DNA vaccine helped lower blood pressure for up to six months, reduced tissue damage to the heart and blood vessels associated with hypertension in rats.
- If future research shows the vaccine is a viable treatment option in humans, it could improve high blood pressure levels.
A vaccine may one day help lower blood pressure for up to six months, according to new research in the American Heart Association’s journal Hypertension.
The study in rats may eventually provide a novel alternative to treat high blood pressure in people, who would not need to take a pill everyday.
“The potential of a vaccine for hypertension offers an innovative treatment that could be very effective for the control of non-compliance which is one of the major problems in the management of hypertensive patients,” said Hironori Nakagami M.D., Ph.D., study co-author and professor at Osaka University in Japan.
Researchers have designed a DNA vaccine that targets angiotensin II ? a hormone that raises blood pressure by causing blood vessels to constrict. This narrowing can increase your blood pressure and force your heart to work harder.
In the study, researchers immunized hypertensive rats three times at two-week intervals with needleless injections. The vaccine not only lowered blood pressure for up to six months, but also reduced tissue damage to the heart and blood vessels associated with hypertension. There were no signs of damage to other organs such as the kidney or liver.
The DNA vaccine works similar to common ACE inhibitor blood pressure medications which help blood vessels relax and open up, which, in turn, lowers blood pressure. Other types of vaccines have been tested for hypertension (e.g. a peptide vaccine), but didn’t have lasting effects and some had undesirable side effects.
The ultimate goal of an anti-hypertensive vaccine is to achieve perfect blood pressure control by improving drug compliance through the vaccine. In addition, in the developing countries like Africa and south Asia, anti-hypertensive drugs such as ARB (angiotensin receptor blockade) are expensive. A DNA vaccine may provide cheaper and effective anti-hypertensive treatments in such countries, researchers said.
Read more: Future vaccine may help lower blood pressure long-term
The Latest on: DNA vaccine
[google_news title=”” keyword=”DNA vaccine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: DNA vaccine
- Sokoto Varsity Researchers Submit COVID 19 Vaccine for Preclinical Trialson February 3, 2023 at 7:52 pm
The UDUS is among the institutions that were engaged by the Tertiary Education Trust Fund (TETFund) under its vaccine development mega-research project to produce COVID vaccines within 18 months. The ...
- Vaccines: Unvaccinated donors block transfusionson February 3, 2023 at 6:57 pm
Some have advocated for blood banks that draw from “pure” unvaccinated people, while medics in North America say they have fielded requests from people demanding transfusions from donors who have not ...
- Zika Virus Vaccine Market 2023 : Top Manufacturers, Key Trends, Progression Status and Business Trends to 2029on February 2, 2023 at 7:38 pm
Zika Virus Vaccine Market Size is projected to Reach Multimillion USD by 2029, In comparison to 2022, at unexpected ...
- Fact Check-COVID-19 vaccines do not add a ‘third strand’ of DNAon February 2, 2023 at 1:36 pm
Moderna’s mRNA COVID-19 vaccine does not alter human DNA or add a third strand to people’s DNA, as claimed in a video circulating on social media and viewed more than 400,000 times on Twitter. The ...
- Inovio Pharma Releases Favorable Data From Booster DNA Vaccine Candidate For Ebolaon February 2, 2023 at 11:53 am
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Trending: Putin To Give A Million Rubles Each To All Women Who Give Birth To ...
- Post misleads on J&J COVID vaccine, DNAon February 2, 2023 at 8:18 am
CLAIM: The COVID-19 vaccine from Johnson & Johnson enters the nucleus of cells, suggesting that the shot alters recipients’ DNA. AP’S ASSESSMENT: Missing context.
- BioNTech to invest $43 mln in German facility for mRNA vaccine building blockon February 2, 2023 at 7:44 am
BioNTech will invest 40 million euros ($43 million) in a new facility in Germany that will allow it to produce an important building block in mRNA-based drugs, the German pharmaceutical firm said on ...
- Researchers report a heterologous vaccination strategy against IBV in Chickenson February 2, 2023 at 7:17 am
Researchers reported on the immunogenicity of a heterologous vaccine regimen against IBV, comprising prime doses of QAC-encapsulated plasmid and a booster dose of MVA.
- Human DNA Vaccines Market 2023 Complete Analytical Report with Huge Business Growth by 2026on February 1, 2023 at 2:01 am
Human DNA Vaccines Market ” 2023 report offers business strategy, covers complete landscape for business development including major regions with the frame of reference historic data. Competitive ...
- New vaccine platform could ease development, delivery of antigenson January 30, 2023 at 9:41 am
To many, EV stands for "electric vehicle." To researchers at Harvard University and the University of Nebraska–Lincoln, it's shorthand for another vehicle—this one nanoscopic—that might help ...
via Bing News